Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 29:10:1706-32.
doi: 10.3762/bjoc.10.179. eCollection 2014.

Multicomponent reactions in nucleoside chemistry

Affiliations
Review

Multicomponent reactions in nucleoside chemistry

Mariola Koszytkowska-Stawińska et al. Beilstein J Org Chem. .

Abstract

This review covers sixty original publications dealing with the application of multicomponent reactions (MCRs) in the synthesis of novel nucleoside analogs. The reported approaches were employed for modifications of the parent nucleoside core or for de novo construction of a nucleoside scaffold from non-nucleoside substrates. The cited references are grouped according to the usually recognized types of the MCRs. Biochemical properties of the novel nucleoside analogs are also presented (if provided by the authors).

Keywords: multicomponent reaction; nucleoside analog; nucleoside antibiotics; nucleoside construction; nucleoside modification.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Selected chemical modifications of natural ribose or 2'-deoxyribose nucleosides leading to the development of medicinally important nucleoside analogs.
Scheme 1
Scheme 1
(a) Classical Mannich reaction; (b) general structures of selected hydrogen active components and structures of the resulting Mannich reaction products.
Scheme 2
Scheme 2
Reagents and reaction conditions: i. H2O or H2O/EtOH, 60–100 °C, 7 h–10 d; ii. H2, Pd/C or PtO2; iii. (1) 4-methylbenzenethiol, (2) Ni-Ra; iv. (1) MeI, (2) NaBH4; v. (1) MeI, (2) nucleophile.
Scheme 3
Scheme 3
Reagents and reaction conditions: i. H2O, 90 °C, overnight.
Scheme 4
Scheme 4
Reagents and reaction conditions: i. AcOH, H2O, 60 °C, 12 h-5 d; ii. AcOH, H2O, 60 °C, 8 h.
Scheme 5
Scheme 5
Reagents and reaction conditions: i. CuBr, THF, reflux, 0.5 h; ii. n-Bu4NF·3H2O, THF, rt, 2 h.
Scheme 6
Scheme 6
Reagents and reaction conditions: i. [bmim][PF6], 80 °C, 5–8 h.
Scheme 7
Scheme 7
Reagents and reaction conditions: i. EtOH, reflux, 24 h.
Scheme 8
Scheme 8
Reagents and reaction conditions: i. NaOAc, H2O, 95 °C, 1–16 h; ii. NaOAc, H2O, 95 °C, 1 h.
Scheme 9
Scheme 9
Reagents and reaction conditions: i. a. 37% aq HCl, MeOH; b. NaOAc, 1,4-dioxane, H2O, 100 °C, overnight.
Scheme 10
Scheme 10
Reagents and reaction conditions: i. DMAP, DCC, MeOH, rt, 1 h.
Scheme 11
Scheme 11
The Kabachnik–Fields reaction.
Scheme 12
Scheme 12
Reagents and reaction conditions: i. 60 °C, 3 h; ii. 80 °C, 2 h.
Scheme 13
Scheme 13
The four-component Ugi reaction.
Scheme 14
Scheme 14
Reagents and reaction conditions: i. MeOH, rt, 2–3 d, yields not given.
Scheme 15
Scheme 15
Reagents and reaction conditions: i. MeOH/CH2Cl2 (1:1), rt, 24 h, yield not given; ii. 6 N aq HCl, 80 °C, 2 h, 80%.
Scheme 16
Scheme 16
Reagents and reaction conditions: i. MeOH/H2O, rt, 26 h; ii. aq AcOH, reflux, 50%; iii. reversed phase HPLC, then MeOH, Pd black, formic acid, 1 h.
Scheme 17
Scheme 17
Reagents and reaction conditions: i. MeOH, rt, 24 h; ii. HCl, MeOH, 0 °C to rt, 6 h, then H2O, rt, 12 h.
Scheme 18
Scheme 18
Reagents and reaction conditions: i. DMF/Py/MeOH (1:1:1), rt, 48 h; ii. 10% HCl/MeOH, rt, 30 min.
Scheme 19
Scheme 19
Reagents and reaction conditions (R = CH3 or H): i. CH2Cl2/MeOH (2:1), 35–40 °C, 2 d; ii. HF/pyridine, THF, rt, 2.5 h, then MeOTMS, rt, 3.5 h.
Scheme 20
Scheme 20
Reagents and reaction conditions: i. MeOH, 76%; ii. 80% aq TFA, 100%.
Scheme 21
Scheme 21
Reagents and reaction conditions: i. EtOH, rt, 72 h; ii. Zn, aq NaH2PO4, THF, rt, 1 week; then 80% aq TFA, rt, 8 h; then HPLC separation.
Scheme 22
Scheme 22
Reagents and reaction conditions: i. EtOH, rt, 48 h, then silica gel chromatography, 33% for 57 (30% for epi-57).
Scheme 23
Scheme 23
Reagents and reaction conditions: i. [bmim]BF4, 80 °C, 4 h; ii. [bmim]BF4, 80 °C, 3 h; iii. [bmim]BF4, 80 °C, 2–4 h; iv. EtOH, 50 °C, overnight.
Scheme 24
Scheme 24
Reagents and reaction conditions: i. [bmim]BF4, 80 °C.
Scheme 25
Scheme 25
Reagents and reaction conditions: i. H3PW12O40 (2 mol %), EtOH, 50 °C, 2–15 h; ii. H3PW12O40 (2 mol %), EtOH, 50 °C, 8 h.
Scheme 26
Scheme 26
General scheme of the Biginelli reaction.
Scheme 27
Scheme 27
Reagents and reaction conditions: i. EtOH, reflux.
Scheme 28
Scheme 28
Reagents and reaction conditions: i. Bu4N+HSO4, diethylene glycol, 120 °C, 1.5–3 h.
Scheme 29
Scheme 29
Reagents and reaction conditions: i. BF3·Et2O, CuCl, AcOH, THF, 65 °C, 24 h; ii. Yb(OTf)3, THF, reflux, 20 h.
Scheme 30
Scheme 30
Reagents and reaction conditions: TCT (10 mol %), rt: i. 100 min; ii. 150 min; iii. 140 min.
Scheme 31
Scheme 31
Reagents and reaction conditions: i. EtOH, microwave irradiation (300 W), 10 min; ii. EtOH, 75 °C, 5 h and for 72 h, rt.
Scheme 32
Scheme 32
The Hantzsch reaction.
Scheme 33
Scheme 33
Reagents and reaction conditions: TCT (10 mol %), rt, 80–150 min.
Scheme 34
Scheme 34
Reagents and reaction conditions: i. Yb(OTf)3, THF, 90 °C, 12 h; ii. 4 Å molecular sieves, EtOH, 90 °C, 48 h.
Scheme 35
Scheme 35
Reagents and reaction conditions: i. MeOH, 50 °C, 48 h.
Scheme 36
Scheme 36
Reagents and reaction conditions: i. MeOH, 25 °C, 5 d.
Scheme 37
Scheme 37
Bu4N+HSO4, diethylene glycol, 80 °C, 1–2 h.
Scheme 38
Scheme 38
The three-component carbopalladation of dienes on the example of buta-1,3-diene.
Scheme 39
Scheme 39
Reagents and reaction conditions: i. 5 mol % Pd(dba)2, Bu4NCl, ZnCl2, acetonitrile or DMSO, 80 °C or 100 °C, 1–2 days.
Scheme 40
Scheme 40
Reagents and reaction conditions: i. 2.5 mol % Pd2(dba)3, tris(2-furyl)phosphine, K2CO3, MeCN or DMF, 80 °C, 3–24 h, 77–99%.
Scheme 41
Scheme 41
Reagents and reaction conditions: i. 2.5 mol % Pd2(dba)3, tris(2-furyl)phosphine, K2CO3, MeCN or DMF, 80 °C, 3–24 h, 45–87%.
Scheme 42
Scheme 42
The three-component Bucherer–Bergs reaction.
Scheme 43
Scheme 43
Reagents and reaction conditions: i. MeOH, H2O, 70 °C, 4.5 h; ii. (1) H2, 5% Pd/C, MeOH, 55 °C, 5 h; (2) Dowex 50 W, MeOH, H2O, rt, 4 h.
Scheme 44
Scheme 44
Reagents and reaction conditions: i. pyridine, MgSO4, 100 °C, 28 h, N2; ii. DMF, 70–90 °C, 22–30 h, N2, the cumulative yield of 108/109 from 55% to 96%.
Scheme 45
Scheme 45
Reagents and reaction conditions: i. Montmorillonite K-10 clay, microwave irradiation (600 W), 6–10 min (solvent-free conditions).
Scheme 46
Scheme 46
Reagents and reaction conditions: i. Montmorillonite K-10 clay, microwave irradiation (560 W), 6–10 min (solvent-free conditions).
Scheme 47
Scheme 47
Reagents and reaction conditions: i. CeCl3·7H2O (20 mol %), NaI (20 mol %), microwave irradiation (90 °C), 6–8 min; ii. CuSO4·5H2O, Al2O3, microwave irradiation (90 °C), 3–3.5 min.
Scheme 48
Scheme 48
Reagents and reaction conditions: i. PhI(OAc)2 (3 mol %), microwave irradiation (45 °C), 6–9 min.
Scheme 49
Scheme 49
Reagents and reaction conditions: i. 117, ethyl pyruvate, TiCl4, dichloromethane, −78 °C, 1 h; then 118, −78 °C, 1 h; then 23 °C, 1 h.

References

    1. Jordheim L P, Durantel D, Zoulim F, Dumontet C. Nat Rev Drug Discovery. 2013;12:447–464. doi: 10.1038/nrd4010. - DOI - PubMed
    1. Struthers H, Viertl D, Kosinski M, Spingler B, Buchegger F, Schibli R. Bioconjugate Chem. 2010;21:622–634. doi: 10.1021/bc900380n. - DOI - PubMed
    1. Wiebe L I. Technetium-99m Radiopharmaceuticals: Status And Trends. Vienna: International Atomic Energy Agency; 2009. Gene and molecular imaging using 99mTc labelled radiopharmaceuticals; pp. 159–163.
    1. Alberto R, N’Dongo H P, Clericuzio M, Bonetti S, Gabano E, Cassino C, Ravera M, Osella D. Inorg Chim Acta. 2009;362:4785–4790. doi: 10.1016/j.ica.2009.06.054. - DOI
    1. Celen S, de Groot T, Balzarini J, Vunckx K, Terwinghe C, Vermaelen P, van Berckelaer L, Vanbilloen H, Nuyts J, Mortelmans L, et al. Nucl Med Biol. 2007;34:283–291. doi: 10.1016/j.nucmedbio.2007.01.003. - DOI - PubMed

LinkOut - more resources